Anna Frances Sullivan Counselor Medicare: Medicare Enrolled Practice Location: 95a Portland Ave, Redding, CT 06896 Phone: 203-312-3889 |
Dana Gestal Frederickson Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 66 Hill Rd, Redding, CT 06896 Phone: 415-730-2744 |
Ms. Nanette Rose Seligman Greene, LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 374 Black Rock Tpke, Redding, CT 06896 Phone: 203-615-3894 |
Ms. Lorena Fernandez Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 11 Beeholm Rd, Redding, CT 06896 Phone: 203-273-5565 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Morphine Sulfate Extended-release (ER) Tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.
Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.
The research, led by Professor Donny Strosberg of Scripps Florida, was published on March 4, 2009, in the Journal of General Virology's advance, online edition, Papers in Press.
Roche announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN's wholly owned subsidiary DxS, now QIAGEN Manchester.
› Verified 9 days ago